Fwd: Expanding Options in HIV

[Guest guest]

•

Expert perspectives

•

Concise 6-8 minute interviews

•

Interactive scientific discourse

Earn CME credits online NOW

Update from IAS, ICAAC & IDSA: Focus on New and Emerging HIV Therapies

Course DirectorIan , MDUniversity of Pennsylvania Center for AIDS ResearchPhiladelphia, Pennsylvania

Go online now to participate in this activity

Dear Colleague,

The options for treating HIV disease have recently expanded with the approval of two first-in-class agents with novel mechanisms of actions. Data on these and other emerging agents within those classes were presented at a number of recent national and international meetings.

This CME activity highlights several key studies.

•

In the first presentation, Kuritzkes, MD, reviews data on the safety and efficacy of the CCR5 entry inhibitors maraviroc and vicriviroc.

•

Next, Anton Pozniak, MD, FRCP, discusses recent data on the integrase inhibitors raltegravir and elvitegravir.

•

In the third presentation, I look at practical issues of integrating these agents into clinical practice, including the identification of patients who are candidates for these agents and the potential for drug-drug interactions.

Sincerely,Ian , MDStart the year off right. Easy ways to stay in shape in the new year.

[Guest guest]

•

Expert perspectives

•

Concise 6-8 minute interviews

•

Interactive scientific discourse

Earn CME credits online NOW

Update from IAS, ICAAC & IDSA: Focus on New and Emerging HIV Therapies

Course DirectorIan , MDUniversity of Pennsylvania Center for AIDS ResearchPhiladelphia, Pennsylvania

Go online now to participate in this activity

Dear Colleague,

The options for treating HIV disease have recently expanded with the approval of two first-in-class agents with novel mechanisms of actions. Data on these and other emerging agents within those classes were presented at a number of recent national and international meetings.

This CME activity highlights several key studies.

•

In the first presentation, Kuritzkes, MD, reviews data on the safety and efficacy of the CCR5 entry inhibitors maraviroc and vicriviroc.

•

Next, Anton Pozniak, MD, FRCP, discusses recent data on the integrase inhibitors raltegravir and elvitegravir.

•

In the third presentation, I look at practical issues of integrating these agents into clinical practice, including the identification of patients who are candidates for these agents and the potential for drug-drug interactions.

Sincerely,Ian , MDStart the year off right. Easy ways to stay in shape in the new year.